Comparing the efficacy of efgartigimod and intravenous immunoglobulin on AQP4‐IgG‐positive neuromyelitis optica spectrum disorder during acute attacks

IF 3 3区医学 Q2 PHARMACOLOGY & PHARMACY

British journal of clinical pharmacology Pub Date : 2025-08-21 DOI:10.1002/bcp.70190

Jia Liu, Min Li, Haotian Wu, Xiaofeng Xu, Kai Dai, Ruiqi Dong, Junyu Liu, Lu Yang, Ying Jiang, Fuhua Peng

{"title":"Comparing the efficacy of efgartigimod and intravenous immunoglobulin on AQP4‐IgG‐positive neuromyelitis optica spectrum disorder during acute attacks","authors":"Jia Liu, Min Li, Haotian Wu, Xiaofeng Xu, Kai Dai, Ruiqi Dong, Junyu Liu, Lu Yang, Ying Jiang, Fuhua Peng","doi":"10.1002/bcp.70190","DOIUrl":null,"url":null,"abstract":"Aims: The aim of our study was to evaluate the efficacy of efgartigimod and intravenous immunoglobulin (IVIG) on AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) patients during acute attacks.Methods: A retrospective case-control study was designed to compare the clinical outcomes of 13 NMOSD patients treated with efgartigimod (at a dose of 20 mg/kg in the first and fifth day) and 20 NMOSD patients treated with IVIG (at 0.4 g/kg/day for 5 days). Follow-up outcome information for patients is documented at 6 months postdischarge.Results: Compared with IVIG, efgartigimod could improve NMOSD patients' symptoms during acute attacks, the mean Expanded Disability Status Scale score was significantly improved from 3.0 at admission to 2.5 at discharge (P < .001). The serum IgG levels were obviously decreased in NMOSD patients treated with efgartigimod (P < .001). Additionally, AQP4-IgG titres in 5 NMOSD patients were found to turn negative after efgartigimod treatment.Conclusion: The efficacy of efgartigimod is comparable to IVIG therapy in improving acute symptoms of AQP4-IgG-positive NMOSD. Efgartigimod could be an elegant alternative to IVIG therapy, and no serious adverse events were observed during infusion.","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of clinical pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/bcp.70190","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: The aim of our study was to evaluate the efficacy of efgartigimod and intravenous immunoglobulin (IVIG) on AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) patients during acute attacks.

Methods: A retrospective case-control study was designed to compare the clinical outcomes of 13 NMOSD patients treated with efgartigimod (at a dose of 20 mg/kg in the first and fifth day) and 20 NMOSD patients treated with IVIG (at 0.4 g/kg/day for 5 days). Follow-up outcome information for patients is documented at 6 months postdischarge.

Results: Compared with IVIG, efgartigimod could improve NMOSD patients' symptoms during acute attacks, the mean Expanded Disability Status Scale score was significantly improved from 3.0 at admission to 2.5 at discharge (P < .001). The serum IgG levels were obviously decreased in NMOSD patients treated with efgartigimod (P < .001). Additionally, AQP4-IgG titres in 5 NMOSD patients were found to turn negative after efgartigimod treatment.

Conclusion: The efficacy of efgartigimod is comparable to IVIG therapy in improving acute symptoms of AQP4-IgG-positive NMOSD. Efgartigimod could be an elegant alternative to IVIG therapy, and no serious adverse events were observed during infusion.

查看原文本刊更多论文

艾加替莫德与静脉注射免疫球蛋白治疗aqp4 - igg阳性视神经脊髓炎急性发作的疗效比较。

目的：评价依加替莫德联合静脉注射免疫球蛋白（IVIG）治疗aqp4 - igg阳性视谱神经脊髓炎（NMOSD）急性发作的疗效。方法：采用回顾性病例对照研究，比较13例NMOSD患者接受依加替莫德治疗（第1天和第5天剂量为20mg /kg）和20例NMOSD患者接受IVIG治疗（0.4 g/kg/天，连续5天）的临床结果。出院后6个月记录患者的随访结果信息。结果：与IVIG相比，艾夫加替莫德可改善NMOSD患者急性发作时的症状，其扩展残疾状态量表平均评分由入院时的3.0分显著提高至出院时的2.5分(P)。结论：艾夫加替莫德在改善aqp4 - igg阳性NMOSD急性症状方面的疗效与IVIG相当。艾夫加替莫德可能是IVIG治疗的一个很好的替代方案，在输注期间没有观察到严重的不良事件。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British journal of clinical pharmacology 医学-药学

CiteScore

6.30

自引率

8.80%

发文量

419

审稿时长

1 months

期刊介绍： Published on behalf of the British Pharmacological Society, the British Journal of Clinical Pharmacology features papers and reports on all aspects of drug action in humans: review articles, mini review articles, original papers, commentaries, editorials and letters. The Journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry. It also publishes research on new methods, new drugs and new approaches to treatment. The Journal is recognised as one of the leading publications in its field. It is online only, publishes open access research through its OnlineOpen programme and is published monthly.